Compare Applovin Corporation (APP) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Applovin Corporation vs BridgeBio Pharma Inc — how do they compare? Applovin Corporation trades at $507.52 (market cap $170.31B), while BridgeBio Pharma Inc trades at $86.91 (market cap $16.81B). The key difference: Applovin Corporation is far larger — about 10.1× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Applovin Corporation nearer its low. Which is the better fit depends on your goals.
| APP | BBIO | |
|---|---|---|
Market Cap | $170.31B | $16.81B |
Sector | Technology | Health |
52-Week High | $733.60 | $90.17 |
52-Week Low | $335.10 | $44.81 |
Enterprise Value | $171.07B | $18.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AppLovin trades at $506.98, down 2.58% today, with a bullish technical setup near pivot point support at $504. The company shows exceptional fundamentals with 59% revenue growth in Q1 2026 and net margins exceeding 64%. Analyst consensus remains strongly bullish with an $644.09 price target, supported by expanding e-commerce advertising share and AI-driven platform growth noted in recent Jefferies research.
The outlook remains positive given consistent earnings beats and projected revenue growth to $6.2B in 2026. Primary risks include premium valuation multiples (P/E 44.09) and competitive pressure in mobile advertising. The stock offers growth exposure but requires monitoring of execution against high expectations.
BridgeBio Pharma (BBIO) trades at $85.89, down 4.75% today but remains near 52-week highs following positive clinical news. The stock shows strong technical momentum with bullish moving averages and support at $85. Fundamentally, revenue grew to $502M in 2025 but net losses widened to -$725M with negative cash flow from operations. Recent news highlights competitor setbacks boosting confidence in Attruby and a $1B preferred equity raise to fund launches.
Outlook hinges on successful drug launches and pipeline execution, with analyst consensus bullish (92% buy ratings) and a $103 price target. Key risks include sustained cash burn, clinical trial outcomes, and high valuation (P/S 28.5) pricing in future success. The stock offers growth potential but requires monitoring of profitability milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applovin Corporation
AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
